Summary
The registration process for new drugs is crucial in the clinical application of medicines. Previously, the registration of imported novel therapeutic agents in Taiwan depended considerably on their approvals in developed countries. The Taiwanese government enacted Article 38–1 of the Regulations for Registration of Medicinal Products in September 2009. According to the new submission criteria, approvals may be exempted if the number of Taiwanese participants in the clinical trials fulfills the required threshold. The present study compared the profiles of clinical trials of novel therapeutic agents before and after the enactment of this regulation in terms of over-threshold trials, structural types, and therapeutic areas across phases. The outcome—whether the liberalization of the submission criteria functioned as an incentive to launch clinical trials in Taiwan—was also evaluated. The results revealed that the number of clinical trial applications increased after the reformed regulation was enacted, even after the over-threshold criteria were considered; however, the increase disappeared for phase III trials. Most clinical trials were for chemical products and antineoplastic agents across all phases and study periods before and after the enactment of Article 38–1. Furthermore, the increase in the number of international clinical trials conducted in Taiwan was not directly caused by the regulation reform because the percentage of investigational products fulfilling the exemption criteria did not increase. These paradoxical results were interpreted in several aspects, referring particularly to the well-established infrastructure for launching clinical trials as well as the integral environment of medical services in Taiwan.
Similar content being viewed by others
References
Ciociola AA, Cohen LB, Kulkarni P (2014) FDA-related matters committee of the American College of Gastroenterology. How drugs are developed and approved by the FDA: current process and future directions Am J Gastroenterol 109:620–623
Barbui C, Bighelli I (2013) A new approach to psychiatric drug approval in Europe. PLoS Med 10:e1001530
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (1998) Ethnic factors in the acceptability of foreign clinical data
Su LL, Chern HD, Lee IL, et al. (2009) An Overview of Bridging Study Evaluation in Taiwan. Ther Innov Regul Sci 43:371–376
Chern HD (1997) Current status of clinical trials and GCP in Taiwan. Ther Innov Regul Sci 31:1097–1103
Hsiao ML (1998) The current status of clinical trials and GCP in Taiwan. Ther Innov Regula Sci 32:1203S–1207S
Taiwan Food and Drug Administration, Ministry of Health and Welfare, Taiwan (2015) Regulations for Registration of Medicinal Products http://law.moj.gov.tw/Eng/LawClass/LawContent.aspx?PCODE=L0030057. Accessed 20 April 2015
Chen CH (2006) Taiwan’s strategy in the establishment of clinical trial infrastructure. APBN 10:1205–1209
Chern HD, Gau CS, Hsu Chen HM, et al. (2009) An experimental model of regulatory science in Asia: Center for Drug Evaluation in Taiwan. Ther Innov Regul Sci 43:301–304
Clinical Trial Network in Taiwan. http://www1.cde.org.tw/ct_taiwan/archive.html. Accessed 20 April 2015
Taiwan Food and Drug Administration, Ministry of Health and Welfare, Taiwan (2013) Pharmaceutical Affairs Act http://law.moj.gov.tw/Eng/LawClass/LawAll.aspx?PCode=L0030001. Accessed 20 April 2015
World Health Organization (WHO) Collaborating Centre for Drug Statistics Methodology (2015) Guideline for ATC classification and DDD assignment
Downing NS, Aminawung JA, Shah ND, et al. (2014) Clinical trial evidence supporting FDA approval of novel therapeutic agents 2005–2012. JAMA 311:368–377
Thatcher N, Chang A, Parikh P, et al. (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527–1537
Wu TY, Majeed A, Kuo KN, et al. (2010) An overview of the healthcare system in Taiwan. London J Prim Care (Abingdon) 3:115–119
Wong E (2009) The regulatory environment and clinical trials in Southeast Asia. Therapeutic Innovation & Regulatory Science 43:57–61
Taiwan Food and Drug Administration, Ministry of Health and Welfare, Taiwan (2014) Regulations for Good Clinical Practice.http://lawmojgovtw/Eng/LawClass/LawContentaspx?PCODE=L0030056 Accessed 20 April 2015
Singh R, Wang O (2013) Clinical trials in "emerging markets": regulatory considerations and other factors. Contemp Clin Trials 36:711–718
Uyama Y, Yamazaki E, Clark K, et al. (2015) General principles for the education and training of GCP inspectors: the outcome of discussions by international regulatory experts in the discussion group on the ICH E6 Guideline. Ther Innov Regul Sci 49:249–253
MacMahon S, Perkovic V, Patel A (2013) Industry-sponsored clinical trials in emerging markets time to review the terms of engagement. JAMA 310:907–908
Zhang D, Yin P, Freemantle N, et al. (2008) An assessment of the quality of randomised controlled trials conducted in China. Trials 9:22–29
Wang L, Li Y, Li J, et al. (2010) Quality of reporting of trial abstracts needs to be improved: using the CONSORT for abstracts to assess the four leading Chinese medical journals of traditional Chinese medicine. Trials 11:75–80
Lido JJ, Liao CC, On A, et al. (2009) Updates on IND process and clinical trials status in Taiwan. Ther Innov Regul Sci 43:63–68
Li YC, Yen JC, Chiu WT, et al. (2015) Building a national electronic medical record exchange system - experiences in Taiwan. Comput Methods Prog Biomed 121:14–20
Chen YC, Chang YJ, Tsou YC, et al. (2013) Effectiveness of nurse case management compared with usual care in cancer patients at a single medical center in Taiwan: a quasi-experimental study. BMC Health Serv Res 13:202–208
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Sun, IC., Shy, HS. & Liao, TY. Effect of regulation reform on clinical trials for registering novel therapeutic agents in Taiwan: a chronological analysis. Invest New Drugs 34, 364–370 (2016). https://doi.org/10.1007/s10637-016-0322-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-016-0322-2